KR20140025326A - 신규 인돌, 인다졸 유도체 또는 그 염 - Google Patents

신규 인돌, 인다졸 유도체 또는 그 염 Download PDF

Info

Publication number
KR20140025326A
KR20140025326A KR1020137017451A KR20137017451A KR20140025326A KR 20140025326 A KR20140025326 A KR 20140025326A KR 1020137017451 A KR1020137017451 A KR 1020137017451A KR 20137017451 A KR20137017451 A KR 20137017451A KR 20140025326 A KR20140025326 A KR 20140025326A
Authority
KR
South Korea
Prior art keywords
group
compound
salt
methyl
substituent
Prior art date
Application number
KR1020137017451A
Other languages
English (en)
Korean (ko)
Inventor
마코토 기타데
슈이치 오쿠보
지호코 요시무라
Original Assignee
다이호야쿠힌고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다이호야쿠힌고교 가부시키가이샤 filed Critical 다이호야쿠힌고교 가부시키가이샤
Publication of KR20140025326A publication Critical patent/KR20140025326A/ko

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020137017451A 2011-01-07 2012-01-06 신규 인돌, 인다졸 유도체 또는 그 염 KR20140025326A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011002147 2011-01-07
JPJP-P-2011-002147 2011-01-07
PCT/JP2012/050140 WO2012093707A1 (ja) 2011-01-07 2012-01-06 新規インドール、インダゾール誘導体又はその塩

Publications (1)

Publication Number Publication Date
KR20140025326A true KR20140025326A (ko) 2014-03-04

Family

ID=46457557

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137017451A KR20140025326A (ko) 2011-01-07 2012-01-06 신규 인돌, 인다졸 유도체 또는 그 염

Country Status (14)

Country Link
US (1) US9120780B2 (zh)
EP (1) EP2662367B1 (zh)
JP (1) JP5865844B2 (zh)
KR (1) KR20140025326A (zh)
CN (1) CN103402995B (zh)
AU (1) AU2012204650A1 (zh)
BR (1) BR112013017416A2 (zh)
CA (1) CA2834101A1 (zh)
ES (1) ES2589557T3 (zh)
HK (1) HK1189384A1 (zh)
MX (1) MX2013007937A (zh)
RU (1) RU2013136861A (zh)
TW (1) TW201309672A (zh)
WO (1) WO2012093707A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1013999B1 (pt) 2009-07-10 2020-06-02 Taiho Pharmaceutical Co., Ltd. Composto de azabiciclo e um sal deste, produto farmacêutico e composição farmacêutica compreendendo dito composto e uso do mesmo para tratar câncer
CN105793421A (zh) * 2013-10-02 2016-07-20 大鹏药品工业株式会社 耐性突变型90kDa热休克蛋白质
CN104744459A (zh) * 2013-12-27 2015-07-01 中国药科大学 吡啶并吡啶酮及其衍生物的合成方法
DE102014106987A1 (de) * 2014-02-14 2015-08-20 Hartmut Yersin Organische TADF-Moleküle mit sterischer Behinderung am Donator und am Akzeptor für opto-elektronische Vorrichtungen
DE102014106986B4 (de) * 2014-02-14 2023-10-12 Samsung Display Co., Ltd. Organische Moleküle mit kleinen Triplett-Singulett-Energieabständen für eine effektive verzögerte Fluoreszenz zur Anwendung in opto-elektronischen Vorrichtungen
CN117003754A (zh) * 2022-04-28 2023-11-07 腾讯科技(深圳)有限公司 吡咯并[2,3-d]嘧啶或吡唑并[3,4-d]嘧啶衍生物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57203068A (en) 1981-06-08 1982-12-13 Teikoku Hormone Mfg Co Ltd Novel 1-phenylisoquinoline derivative
AR028782A1 (es) 2000-07-05 2003-05-21 Taisho Pharmaceutical Co Ltd Derivados heterociclicos tetrahidropiridino o piperidino
MX2008003202A (es) * 2005-09-16 2008-03-25 Serenex Inc Derivados de carbazol.
RS53446B (en) * 2006-05-25 2014-12-31 Synta Pharmaceuticals Corp. TRIAZOLE UNITS MODULATING HSP90 ACTIVITY
WO2008024978A2 (en) * 2006-08-24 2008-02-28 Serenex, Inc. Tetrahydroindolone and tetrahydroindazolone derivatives
WO2008026704A1 (fr) 2006-08-31 2008-03-06 Kyowa Hakko Kogyo Co., Ltd. Dérivé d'isoquinoline
CA2705318C (en) 2007-11-15 2013-12-31 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
EP2229381A1 (en) * 2007-12-06 2010-09-22 Schering Corporation Gamma secretase modulators
FR2928645A1 (fr) 2008-03-14 2009-09-18 Sanofi Aventis Sa Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation
GB0807910D0 (en) 2008-04-30 2008-06-04 Glaxo Group Ltd Compounds
AR075874A1 (es) * 2009-03-19 2011-05-04 Sanofi Aventis Derivados de indazol inhibidores de hsp90 composiciones que los contienen y utilizacion
BRPI1013999B1 (pt) 2009-07-10 2020-06-02 Taiho Pharmaceutical Co., Ltd. Composto de azabiciclo e um sal deste, produto farmacêutico e composição farmacêutica compreendendo dito composto e uso do mesmo para tratar câncer

Also Published As

Publication number Publication date
MX2013007937A (es) 2013-11-01
AU2012204650A1 (en) 2013-08-01
EP2662367A4 (en) 2014-06-25
WO2012093707A1 (ja) 2012-07-12
EP2662367A1 (en) 2013-11-13
HK1189384A1 (zh) 2014-06-06
RU2013136861A (ru) 2015-02-20
TW201309672A (zh) 2013-03-01
US9120780B2 (en) 2015-09-01
CN103402995A (zh) 2013-11-20
CN103402995B (zh) 2016-08-31
EP2662367B1 (en) 2016-08-17
ES2589557T3 (es) 2016-11-15
CA2834101A1 (en) 2012-07-12
US20130289072A1 (en) 2013-10-31
BR112013017416A2 (pt) 2019-09-24
JP5865844B2 (ja) 2016-02-17
JPWO2012093707A1 (ja) 2014-06-09

Similar Documents

Publication Publication Date Title
JP7482918B2 (ja) Cdk阻害剤としての置換型ヘテロシクリル誘導体
AU2020273302B2 (en) Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer
RU2625303C2 (ru) Хинолины в качестве модуляторов fgfr киназы
TW202104189A (zh) 雙環化合物
TW201400486A (zh) 作爲激酶抑制劑之咪唑并[1,2-b]嗒□衍生物
EA029892B1 (ru) Азотсодержащее гетероциклическое соединение
JP5518902B2 (ja) ヘテロアリール置換ピリダジノン誘導体
EP3083631B1 (en) Wnt pathway modulators
US20190071416A1 (en) Compounds for treatment of cancer and epigenetics
JP5865844B2 (ja) 新規インドール、インダゾール誘導体又はその塩
US11008318B2 (en) 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity
JP2014122161A (ja) ピラゾール化合物
EP3741752A1 (en) Tam family kinase /and csf1r kinase inhibitor and use thereof
EP3768670A1 (en) Imidazolidin-2-one compounds as prmt5 modulators
KR20140025327A (ko) 신규 2 고리형 화합물 또는 그 염
CN118055933A (zh) 选择性parp1抑制剂及其应用
AU2016275210B2 (en) Novel heterocyclic compound, method for preparing the same, and pharmaceutical composition comprising the same
KR20160018686A (ko) 이환식 함질소 방향족 헤테로고리 아미드 화합물
WO2011019060A1 (ja) ヘッジホッグシグナル阻害剤
JP2019001715A (ja) 三環性化合物
TWI759829B (zh) 作為第iii型受體酪胺酸激酶抑制劑之雜環吡唑衍生物
CA3220090A1 (en) Pyrimidine and pyridine amine compounds and usage thereof in disease treatment
JP2024511389A (ja) キナーゼ薬剤耐性変異に関連する疾患を治療するための複素環式化合物の使用及び方法
WO2024097953A1 (en) Naphthyridine compounds for inhibition of raf kinases

Legal Events

Date Code Title Description
A201 Request for examination
WITB Written withdrawal of application